---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042193"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:02:06.585455+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience awarded $10M from ARPA-H to develop HPV treatment candidate DARE-HPV

## Summary
- Award of $10M from ARPA-H Sprint for Women's Health; milestone-based payments over 24 months.
- DARE-HPV: investigational fixed-dose lopinavir/ritonavir vaginal insert for HPV-related cervical diseases.
- Milestones include IND-enabling studies, FDA IND clearance, clinical supplies, and Phase 2 trial start.
- More than half of award payable in first 12 months; ARPA-H retains certain IP rights including march-in.

## SEC filing metadata
- accession: 0001493152-24-042193
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224042193/0001493152-24-042193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224042193/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042193
- JSON: https://secwatch.observer/filing/0001493152-24-042193.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.